NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY IN WHOLE OR IN PART IN AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, THE UNITED STATES OR ANY JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES IN ACCORDANCE WITH APPLICABLE LAW. FOR FURTHER INFORMATION REFER TO "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

First day of subscription for MediTuner's offering in connection with listing on NGM Growth Market

The subscription period for MediTuner AB:s (the "Company") offering in connection with the listing on NGM Growth Market (the “Listing”) begins today (the "Offering").

The Offering in brief

- The Offering comprises 3,243,244 newly issued shares in the Company at a subscription price of SEK 9.25 per share, corresponding to issue proceeds, if the Offering is fully subscribed, of approximately SEK 30.0 million in cash before deduction of costs related to the Offering.
- The subscription period starts today, the 26 November 2026, and ends on 9 December 2026 at 15:00 CET.
- The subscription price is SEK 9.25 per share and corresponds to a market value of approximately SEK 45 million for all 4,870,610 existing shares before the Offering.
- The Company has received subscription undertakings totaling SEK 9.3 million, corresponding to 31.0 percent of the Offering if fully subscribed and 46.5 percent of the minimum threshold of SEK 20 million, from, among others, Cosigrande AB, Konvexitet AB, Claes Dinkelspiel (privately and through Gummesson Gruppen AB), Aoba Invest AB and ALMI Invest (through ALMI Invest AB and ALMI Invest Stockholm AB).
- The Offering is directed to the general public in Sweden as well as institutional investors in Sweden. Minimum subscription is SEK 5,920 and thereafter in any number of shares.
- The minimum threshold for the completion of the Offering is SEK 20 million. If the minimum threshold is not reached, the Offering will not be completed, and the planned Listing will not proceed.
- First day of trading in the Company's shares on NGM Growth Market is expected to be 22 December 2026 and the share will be traded under the ticker symbol MEDTUN (ISIN SE0030614426).
- Board members, management and larger shareholders together holding approximately 51.4 percent of the shares and votes in the Company prior to the share issue, have entered into lock-up agreements for a period of 360 days from the first day of trading.

Documentation

The Company has prepared an information memorandum in connection with the Offering. The information memorandum contains the complete terms and conditions for the Offering and is available on MediTuner's website (www.medituner.com) and on Nordic Issuing's website (www.nordic-issuing.se).

Preliminary timetable

26 November – 9 December 2026	Subscription period
10 December 2026	Estimated date for publication of the outcome
14 December 2026	Estimated settlement day
22 December 2026	Estimated first day of trading on NGM Growth Market

Advisers

Redeye Corporate Finance AB acts as financial adviser to the Company in connection with the Offering and the Listing. Advokatfirman Lindahl KB acts as legal adviser to the Company. Nordic Issuing AB acts as issuing agent. Redeye Nordic Growth AB is the Company's Mentor.

For more information

Eric Alhanko, CEO
+46 (0) 79 332 64 10
eric.alhanko@medituner.se

About MediTuner

MediTuner AB (publ) is a Swedish medtech company with origin in clinical research at Karolinska Institutet, developing digital solutions for self-care and follow-up of respiratory diseases. Founded 2014. Headquarters in Stockholm. www.medituner.com

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer to sell or a solicitation of any offer to buy or subscribe for any securities in the Company in any jurisdiction where such offer or invitation would be unlawful or require additional registration or other measures.

This press release is not a prospectus for the purposes of the Prospectus Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") and has not been approved or reviewed by any regulatory authority in any jurisdiction. No prospectus has been or will be prepared in connection with the Offering.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland, the United States, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release does not constitute an offer of securities to the public in the United Kingdom, and no prospectus has been or will be approved in the United Kingdom in respect of the securities. In the United Kingdom, this press release is only being distributed to, and is only directed at "qualified investors" (as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024) who are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**") or (ii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2) (a) to (d) of the Order (all such persons together being referred to as "**relevant persons**"). In the United Kingdom, any investment or investment activity to which this press release relates is available only to, and will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision in connection with the Offering must be made on the basis of all publicly available information relating to the Company and the Company's shares. Such information has not been independently verified by Redeye. Redeye is acting for the Company in connection with the transaction and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the Offering or any other matter referred to herein.

This press release does not constitute an invitation to warrant, subscribe, or otherwise acquire or transfer any securities in any jurisdiction. This press release does not constitute a recommendation for any investors' decisions regarding the Offering. Each investor or potential investor should conduct a self-examination, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities can decrease as well as increase. Achieved results do not provide guidance for future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release.

Failure to follow these instructions may result in a breach of the Securities Act or applicable laws in other jurisdictions.

The Company considers that it carries out protection-worthy activities under the Foreign Direct Investment Screening Act (the "**Swedish FDI Act**") (Sw. *lag (2023:560) om granskning av utländska direktinvesteringar*). According to the Swedish FDI Act, the Company must inform prospective investors that the Company's activities may fall under the regulation and that the investment may be subject to mandatory filing. If an investment is subject to mandatory filing, it must, prior to its completion, be filed with the Inspectorate of Strategic Products (the "**ISP**"). An investment may be subject to mandatory filing if i) the investor, a member of the investor's ownership structure or a person on whose behalf the investor is acting would, after the completion of the investment, hold votes in the Company equal to, or exceeding any of the thresholds of 10, 20, 30, 50, 65 or 90 per cent of the total number of votes in the Company, ii) the investor would, as a result of the investment, acquire the Company, and the investor, a member of the investor's ownership structure or a person on whose behalf the investor is acting, would, directly or indirectly, hold 10 per cent or more of the total number of votes in the Company, or iii) the investor, a member of the investor's ownership structure or a person on whose behalf the investor is acting, would acquire, as a result of the investment, direct or indirect influence on the management of the Company. The investor may be imposed an administrative sanction charge if a mandatory filing investment is carried out before the ISP either i) decided to leave the notification without action or ii) approved the investment. Each investor should consult an independent legal adviser on the possible application of the Swedish FDI Act in relation to the Offering for the individual investor.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or NGM Growth Market's rule book for issuers.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("**MiFID II**"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "**MiFID II Product Governance Requirements**"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in MediTuner have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "**Target Market Assessment**"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares in MediTuner may decline and investors could lose all or part of their investment; the shares in MediTuner offer no guaranteed income and no capital protection; and an investment in the shares in MediTuner is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering. Furthermore, it is noted that, notwithstanding the Target Market Assessment, Redeye will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II or UK MiFIR; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in MediTuner.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in MediTuner and determining appropriate distribution channels.

Contacts
Eric Alhanko, CEO
Phone +46 79-3326410
Email: eric.alhanko@medituner.se

Anja Peters Ohlsson, CFO and IR
Phone +46 79-3326410
Email: anja.peters@medituner.com, ir@medituner.com

Website: www.medituner.com

About Us

MediTuner AB (publ) is a Swedish MedTech company developing a digital platform for the diagnosis and management of chronic respiratory diseases. The modular platform combines a patient app, wireless spirometer and clinical portal. Powered by a patented treatment algorithm, the app provides patients with personalized instructions on how to adjust their daily medication within a clinician-prescribed treatment plan, while enabling healthcare professionals to evaluate treatment remotely.